CBIO News and Press, Catalyst Biosciences Inc.

Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs ASCEND Phase 1/2 global clinical trial underway to evaluate CR-001 in advanced solid tumors with three additional clinical trials...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that managem...

Travere Therapeutics Inc. (TVTX) is expected to report $0.03 for Q4 2025 Teck Resources Ltd (TECK) is expected to report $0.59 for Q4 2025 Heidmar Maritime Holdings Corp. (HMR) is expected to report $0.05 for Q4 2025 Endava plc American Depositary Shares (each representing one Class A...

ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patients Company anticipates reporting proof-of-concept data in the first quarter of 2027 ASCEND...

Baxter International Inc. (BAX) is expected to report $0.53 for Q4 2025 Nova Ltd. (NVMI) is expected to report $1.94 for Q4 2025 West Pharmaceutical Services Inc. (WST) is expected to report $1.83 for Q4 2025 Universal Logistics Holdings Inc. (ULH) is expected to report $-0.05 for Q4 ...

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that managem...

CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with proof-of-concept data anticipated in first quarter of 2027 Crescent partner Kelun-Biotech receives IND ap...

2025-12-04 16:06:27 ET Stephen Willey from Stifel Nicolaus issued a price target of $32.00 for CBIO on 2025-12-04 20:32:33. The adjusted price target was set to $32.00. At the time of the announcement, CBIO was trading at $12.99. The overall price target consensus is at ...

2025-12-04 09:42:50 ET DENVER, Colo., Dec 04, 2025 ( 247marketnews.com )- Markets begin the morning with a distinctly innovation-heavy tone, as developments across next-generation biotech, quantum-class computing, artificial organs, and global gaming platforms shape today’s early...